Omeros Co. (NASDAQ:OMER) – Analysts at Cantor Fitzgerald decreased their FY2017 earnings per share (EPS) estimates for shares of Omeros in a report issued on Tuesday. Cantor Fitzgerald analyst E. Piros now anticipates that the firm will earn ($1.01) per share for the year, down from their previous estimate of ($0.53). Cantor Fitzgerald currently has a “Overweight” rating and a $21.00 target price on the stock.
OMER has been the topic of a number of other reports. Zacks Investment Research lowered shares of Omeros from a “hold” rating to a “sell” rating in a report on Wednesday, January 4th. Wedbush restated an “outperform” rating and issued a $47.00 price objective on shares of Omeros in a report on Wednesday, February 8th. Maxim Group restated a “buy” rating on shares of Omeros in a report on Wednesday, March 1st. FBR & Co restated a “buy” rating on shares of Omeros in a report on Thursday, March 2nd. Finally, Cowen and Company restated an “outperform” rating on shares of Omeros in a report on Monday, March 20th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $33.38.
COPYRIGHT VIOLATION WARNING: This story was first published by Web Breaking News and is the property of of Web Breaking News. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at http://www.webbreakingnews.com/2017/03/25/fy2017-eps-estimates-for-omeros-co-reduced-by-cantor-fitzgerald-omer.html.
Omeros (NASDAQ:OMER) opened at 11.56 on Thursday. Omeros has a 12 month low of $7.20 and a 12 month high of $16.38. The firm has a 50 day moving average of $11.32 and a 200-day moving average of $10.53. The firm’s market cap is $506.58 million.
A number of large investors have recently made changes to their positions in OMER. First Allied Advisory Services Inc. bought a new stake in shares of Omeros during the fourth quarter valued at approximately $108,000. Nwam LLC raised its stake in shares of Omeros by 12.5% in the third quarter. Nwam LLC now owns 23,393 shares of the biopharmaceutical company’s stock valued at $261,000 after buying an additional 2,600 shares in the last quarter. Gradient Investments LLC raised its stake in shares of Omeros by 3.3% in the third quarter. Gradient Investments LLC now owns 25,285 shares of the biopharmaceutical company’s stock valued at $282,000 after buying an additional 814 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in shares of Omeros during the fourth quarter valued at approximately $263,000. Finally, Raymond James Financial Services Advisors Inc. raised its stake in shares of Omeros by 52.1% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 34,258 shares of the biopharmaceutical company’s stock valued at $340,000 after buying an additional 11,734 shares in the last quarter. Hedge funds and other institutional investors own 47.94% of the company’s stock.
Omeros Company Profile
Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement.
Receive News & Ratings for Omeros Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Co. and related companies with MarketBeat.com's FREE daily email newsletter.